Literature DB >> 24721756

Severity of leukoaraiosis, leptomeningeal collaterals, and clinical outcomes after intra-arterial therapy in patients with acute ischemic stroke.

Dan-Victor Giurgiutiu1, Albert J Yoo2, Kaitlin Fitzpatrick3, Zeshan Chaudhry2, Thabele Leslie-Mazwi4, Lee H Schwamm3, Natalia S Rost3.   

Abstract

BACKGROUND AND
PURPOSE: Leukoaraiosis (LA) is defined as ischemic white matter lesions associated with increased stroke risk and poor post-stroke outcomes. These lesions are likely the result of diffuse angiopathic changes affecting the cerebral small vessels. We investigated whether pre-existing LA burden is associated with outcomes in patients with large cerebral artery occlusion undergoing intra-arterial therapy (IAT) for acute ischemic stroke (AIS).
METHODS: We analyzed consecutive AIS subjects undergoing IAT from the institutional Get With The Guidelines-Stroke database enrolled between January 1, 2007 and June 30, 2009, who had National Institutes of Health Stroke Scale scores of ≥ 8, baseline diffusion weighted imaging volume ≤ 100 mL, and evidence of proximal artery occlusion (PAO) on pre-IAT computed tomography angiography (CTA). LA volume (LAv) was assessed on fluid attenuated inversion recovery MRI using a validated semi-automated protocol. We used CTA for collateral grade, post-IAT angiogram for recanalization status (Thrombolysis in Cerebral Infarction score ≥ 2b), and the 24 h head CT for symptomatic intracranial hemorrhage. Logistic regression was used to determine independent predictors of 90 day post-stroke good functional outcome (modified Rankin Scale score ≤ 2) and mortality.
RESULTS: Increasing LAv independently reduced the odds of good collateral grade (OR 0.85, 95% CI 0.73 to 0.98). Good functional outcome was independently predicted by intravenous tissue plasminogen activator use (OR 12.86, 95% CI 2.20 to 76.28), and recanalization status (OR 6.94, 95% CI 1.56 to 30.86). Mortality was independently associated with recanalization status (OR 0.08, 95% CI 0.01 to 0.51), age (OR 1.08, 95% CI 1.01 to 1.15), and antecedent use of hypoglycemic agents (OR 6.55, 95% CI 1.58 to 54.01).
CONCLUSIONS: Severity of LA is linked to poor collateral grade in AIS patients undergoing IAT for PAO; however, greater LAv appears not to be a contraindication for acute intervention. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24721756     DOI: 10.1136/neurintsurg-2013-011083

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  17 in total

1.  White matter burden does not influence the outcome of mechanical thrombectomy.

Authors:  Laura Mechtouff; Norbert Nighoghossian; Camille Amaz; Marielle Buisson; Yves Berthezène; Laurent Derex; Elodie Ong; Omer Faruk Eker; Tae-Hee Cho
Journal:  J Neurol       Date:  2019-11-08       Impact factor: 4.849

Review 2.  Association between Leukoaraiosis and Poor Outcome is not due to Reperfusion Inefficiency after Intravenous Thrombolysis.

Authors:  Genlong Zhong; Shenqiang Yan; Sheng Zhang; Qingmeng Chen; Yangxiao Lai; Min Lou
Journal:  Transl Stroke Res       Date:  2016-06-02       Impact factor: 6.829

Review 3.  Recent Advances in Leukoaraiosis: White Matter Structural Integrity and Functional Outcomes after Acute Ischemic Stroke.

Authors:  Mark R Etherton; Ona Wu; Natalia S Rost
Journal:  Curr Cardiol Rep       Date:  2016-12       Impact factor: 2.931

4.  Cerebral perfusion and compensatory blood supply in patients with recent small subcortical infarcts.

Authors:  Salvatore Rudilosso; Carlos Laredo; Marco Mancosu; Nuria Moya-Planas; Yashu Zhao; Oscar Chirife; Ángel Chamorro; Xabier Urra
Journal:  J Cereb Blood Flow Metab       Date:  2018-02-13       Impact factor: 6.200

5.  Leukoaraiosis May Confound the Interpretation of CT Perfusion in Patients Treated with Mechanical Thrombectomy for Acute Ischemic Stroke.

Authors:  S Rudilosso; C Laredo; C Vivancos; X Urra; L Llull; A Renú; V Obach; Y Zhao; J L Moreno; A Lopez-Rueda; S Amaro; Á Chamorro
Journal:  AJNR Am J Neuroradiol       Date:  2019-07-25       Impact factor: 3.825

6.  White Matter Integrity and Early Outcomes After Acute Ischemic Stroke.

Authors:  Mark R Etherton; Ona Wu; Anne-Katrin Giese; Arne Lauer; Gregoire Boulouis; Brittany Mills; Lisa Cloonan; Kathleen L Donahue; William Copen; Pamela Schaefer; Natalia S Rost
Journal:  Transl Stroke Res       Date:  2019-01-28       Impact factor: 6.829

7.  Reduced Leukoaraiosis, Noncardiac Embolic Stroke Etiology, and Shorter Thrombus Length Indicate Good Leptomeningeal Collateral Flow in Embolic Large-Vessel Occlusion.

Authors:  T Hashimoto; T Kunieda; T Honda; F Scalzo; L Ali; J D Hinman; N M Rao; M Nour; M Bahr-Hosseini; J L Saver; R Raychev; D Liebeskind
Journal:  AJNR Am J Neuroradiol       Date:  2021-11-18       Impact factor: 3.825

8.  FLAIR Vascular Hyperintensity is a Surrogate of Collateral Flow and Leukoaraiosis in Patients With Acute Stroke Due to Proximal Artery Occlusion.

Authors:  Hasan H Karadeli; Dan-Victor Giurgiutiu; Lisa Cloonan; Kaitlin Fitzpatrick; Allison Kanakis; Muhammed E Ozcan; Lee H Schwamm; Natalia S Rost
Journal:  J Neuroimaging       Date:  2015-08-06       Impact factor: 2.486

9.  Effects of White Matter Hyperintensities on 90-Day Functional Outcome after Large Vessel and Non-Large Vessel Stroke.

Authors:  Christoph Johannes Griessenauer; David McPherson; Andrea Berger; Ping Cuiper; Nelson Sofoluke; Matthew D Adams; Saran Kunaprayoon; Ramin Zand; Jiang Li; Vida Abedi; Oded Goren; Clemens M Schirmer; Kathleen Donahue; Marco Nardin; Anne-Karin Giese; Markus D Schirmer; Natalia S Rost; Philipp Hendrix
Journal:  Cerebrovasc Dis       Date:  2020-07-21       Impact factor: 2.762

10.  Association of FLAIR vascular hyperintensity and acute MCA stroke outcome changes with the severity of leukoaraiosis.

Authors:  W J Shang; L M Shu; X Zhou; H Q Liao; X H Chen; H Hong; H B Chen
Journal:  Neurol Sci       Date:  2020-05-06       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.